Drug intelligence / Profile preview

gp96-Ig

Development stage
Phase 1
Lead developer
Tivic Health Systems
Modality
Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration
Intradermal
01

Overview

gp96-Ig is a secreted recombinant form of the heat shock protein gp96 (also known as Grp94 or ERp99), which is naturally found in the endoplasmic reticulum. The secretory form is created by replacing the C-terminal KDEL retention sequence of human gp96 with the hinge region and constant heavy chains (CH2 and CH3) of mouse or human IgG1.\n\ngp96-Ig functions as both an adjuvant and antigen carrier in vaccine formulations. It activates antigen presenting cells (APCs) including dendritic cells, natural killer cells, and cytotoxic T lymphocytes, while efficiently chaperoning peptides for cross-presentation via MHC I to CD8+ T cells. This dual functionality makes it particularly effective at generating robust CD8+ T cell responses at extremely low antigen concentrations.\n\nA key advantage of gp96-Ig vaccines is their ability to induce both systemic immunity (in blood and spleen) and mucosal immunity at potential pathogen entry sites such as the gut, reproductive tract, and lungs. The vaccine approach has been tested in various disease contexts including cancer (particularly non-small cell lung cancer) and infectious diseases like HIV/SIV, malaria, Zika virus, cytomegalovirus, and COVID-19.

Other names
secreted heat shock protein gp96-Iggp96-immunoglobulingp-96-immunoglobulingp 96-immunoglobulinsecreted gp96-Igsecreted form of heat shock protein gp96viagenpumatucel-L
02

Targets

LRP1 (Prolow-density lipoprotein receptor-related protein 1)

Beyond the preview

Go deeper on gp96-Ig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gp96-Ig.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call